countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study // The Lancet, 2020, 396. P. 1285–1306.

595

J. Cummings et al. Alzheimer’s disease drug development pipeline: 2020, Alzheimer’s and Dementia: Translational Research and Clinical Interventions, 2020, 6. e12050.

596

P. Sebastiani et al. Genetic Signatures of Exceptional Longevity in Humans // PLoS One, 2012, 7.

597

A. D. Roses. Apolipoprotein E affects the rate of Alzheimer’s disease expression: β-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease // Journal of Neuropathology and Experimental Neurology, 1994, 53. P. 429–437.

598

B. J. Morris et al. FOXO3: A Major Gene for Human Longevity — A Mini-Review // Gerontology, 2015, 61. P. 515–525.

599

E. Pennisi. Biologists revel in pinpointing active genes in tissue samples // Science, 2021, 371. P. 1192, 1193.

600

J. L. Platt and M. Cascalho. New and old technologies for organ replacement // Current Opinion in Organ Transplantation, 2013, 18. P. 179–185.

601

M. Cascalho and J. L. Platt. The future of organ replacement: needs, potential applications, and obstacles to application // Transplantation Proceedings, 2006, 38. P. 362–364.

602

L. Xu et al. CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia // New England Journal of Medicine, 2019, 381. P. 1240–1247.

603

K. Musunuru et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates // Nature, 2021, 593. P. 429–434.

604

M. H. Porteus. A New Class of Medicines through DNA Editing // New England Journal of Medicine, 2019, 380. P. 947–959.

605

H. Li et al. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects // Signal Transduction and Targeted Therapy, 2020, 5. P. 1.

606

C. Sagan. Cosmos. Random House, 1980.